Results 221 to 230 of about 27,119,175 (328)

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

The Price Statistics of the Federal Goverment [PDF]

Price Statistics Review Committee
core   +12 more sources

Judicial Review in Italian Administrative Law

, 1959
Giuseppino Treves
openalex   +2 more sources

Health Equity in Systematic Reviews: A Tutorial-Part 2 Implementing Health Equity Throughout Your Methods. [PDF]

Cochrane Evid Synth Methods
Petkovic J, Pardo JP, Welch V, Dewidar O, Maxwell LJ, Darzi A, Lotfi T, Mbuagbaw L, Pottie K, Tugwell P.   +9 more
europepmc   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Intentional creation of suboptimal, realistic dose distributions. [PDF]

J Appl Clin Med Phys
Gay SS, Gronberg MP, Mumme R, Beadle BM, Jhingran A, Lim TY, Yu ZH, Chung C, Khan M, Pinnix C, Shete S, Parker B, Netherton TJ, Cardenas CE, Court LE.   +14 more
europepmc   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

AUTHOR INDEX Volume 35 (1-2); 2012 [PDF]

Macedonian Veterinary Review, 2012
Macedonian Veterinary Review
doaj  

Studies in the Life History of the Song Sparrow, by Margaret Nice Morse [Review]

, 1937
Aldo Leopold
openalex   +2 more sources

Barriers and Facilitators for Implementation of Palliative Care for Patients with Heart failure - a Rapid Synthesis of Reviews. [PDF]

Curr Heart Fail Rep
Grice-Jackson T, Jaarsma P, Friedrichsen M, Wallin MI, De Graaf E, Strömberg A, Jaarsma T.   +6 more
europepmc   +1 more source